•  
  •  
  •  
  •  

2025-11-25 17:54:26

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • DoT grants UL VNO-GMPCS to Nelco Ltd
  • Cybele Industries Ltd has sold land for Rs. 13.10 crore
  • Mangalam Drugs and Organics Ltd receives repeat export order worth Rs. 15 crore
  • Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
  • Firstsource recognized as a 'Leader' in Digital Operations in ISG Provider Lens® 2025

Keywords Selected:  ZydusLifesciences

Stock Report

  • Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
  • Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial
  • Closure of USFDA inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
  • Zydus' Amplitude receives CE mark for its robotic surgical system 'Andy'
  • Zydus receives approval from China's NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg
  • Zydus receives tentative approval from USFDA for Olaparib Tablets, 100 mg and 150 mg
  • Zydus receives tentative approval from USFDA for Budesonide delayedrelease capsules, 4 mg
  • Zydus receives approval from Health Canada for Mesalamine suppositories
  • Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
  • Zydus receives final approval from USFDA for Deflazacort oral suspension, 22.75 mg/mL
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Zydus and Pinkathon join hands to drive awareness on breast cancer across India
  • Zydus receives EIR for the oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • ZyVet® launches affordable Furosemide tablets to support long-term heart care trusted diuretic for dogs and cats now available in a generic form
  • ZyVet® Launches First Generic Treatment for Canine Urinary Incontinence
  • Closure of USFDA inspection at Zydus' injectable manufacturing plant at Jarod
  • Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules for the U.S. market
  • Zydus launches VaxiFlu™ India's first trivalent influenza vaccine for flu protection
  • Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
  • Zydus receives final approval from USFDA for Prucalopride Tablets, 1 mg and 2 mg
  • Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 & 1 mg
  • Zydus announces completion of the acquisition of an 85.6% stake in Amplitude Surgical
  • Zydus receives tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg

Latest Post

  • DoT grants UL VNO-GMPCS to Nelco Ltd
  • Cybele Industries Ltd has sold land for Rs. 13.10 crore
  • Mangalam Drugs and Organics Ltd receives repeat export order worth Rs. 15 crore
  • Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
  • Firstsource recognized as a 'Leader' in Digital Operations in ISG Provider Lens® 2025


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024